Surgery Partners, Inc. (SGRY)
| Market Cap | 1.78B -39.3% |
| Revenue (ttm) | 3.37B +4.0% |
| Net Income | -88.60M |
| EPS | -0.69 |
| Shares Out | 129.71M |
| PE Ratio | n/a |
| Forward PE | 24.76 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,039,008 |
| Open | 13.87 |
| Previous Close | 13.93 |
| Day's Range | 13.52 - 13.98 |
| 52-Week Range | 11.41 - 23.44 |
| Beta | 1.94 |
| Analysts | Buy |
| Price Target | 18.73 (+36.82%) |
| Earnings Date | Aug 10, 2026 |
About SGRY
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care faciliti... [Read more]
Financial Performance
In 2025, Surgery Partners's revenue was $3.31 billion, an increase of 6.24% compared to the previous year's $3.11 billion. Losses were -$77.90 million, -53.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SGRY stock is "Buy." The 12-month stock price target is $18.73, which is an increase of 36.82% from the latest price.
News
Surgery Partners price target raised to $19 from $17 at TD Cowen
TD Cowen raised the firm’s price target on Surgery Partners (SGRY) to $19 from $17 and keeps a Buy rating on the shares. The firm said Management reiterated 2026 revenue/EBITDA…
Surgery Partners’ improved cash conversion not priced in, says Cantor Fitzgerald
Surgery Partners (SGRY)’ Idaho Falls divestiture should improve cash conversion, reduce leverage, and accelerate ex-Idaho Falls organic growth, reinforcing the long-term growth outlook alongside favor...
Surgery Partners price target lowered to $19 from $20 at RBC Capital
RBC Capital lowered the firm’s price target on Surgery Partners (SGRY) to $19 from $20 and keeps an Outperform rating on the shares. The company posted solid results with revenue…
Surgery Partners Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, with revenue and adjusted EBITDA growth driven by higher acuity procedures and strong physician recruitment. The pending Idaho Falls divestiture will simplify the business, reduce leverage, and sharpen focus on core short-stay surgical facilities. Full-year guidance is reaffirmed, with updated outlook to follow transaction close.
Surgery Partners Earnings release: Q2 2026
Surgery Partners released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Surgery Partners Slides: Q2 2026
Surgery Partners has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Surgery Partners Quarterly report: Q2 2026
Surgery Partners has published its Q2 2026 quarterly earnings report on August 10, 2026.
Surgery Partners reports Q2 adjusted EPS 10c, consensus 7c
Reports Q2 revenue $848.9M, consensus $830.32M. Same-facility revenues increased 5% for the second quarter. Eric Evans, Chief Executive Officer, stated, “We are pleased with our progress this quarter,...
Surgery Partners backs FY26 revenue view $3.35B-$3.45B, consensus $3.41B
The company said, “The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million,…
Surgery Partners to sell Mountain View, Idaho Falls hospitals interest for $1.5B
Surgery Partners (SGRY) announced it, along with its existing partner Intermountain Health, has placed into escrow signature pages to definitive agreements, pursuant to which Surgery Partners would se...
Surgery Partners Announces Entry Into Agreement to Sell Ownership Interests in Idaho Falls Facilities to Intermountain Health; Reaffirms Guidance, Excluding Impact of Transaction
BRENTWOOD, Tenn., July 24, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announc...
Surgery Partners price target raised to $17 from $15 at Jefferies
Jefferies raised the firm’s price target on Surgery Partners (SGRY) to $17 from $15 and keeps a Buy rating on the shares. The firm says the company had a good…
Surgery Partners Earnings Call Transcript: Q1 2026
First quarter 2026 results met expectations with $811M revenue and 4.4% same-facility growth, supported by strong MSK performance and disciplined cost management. Guidance for 2026 is reiterated, with ongoing focus on organic growth, margin improvement, and portfolio optimization.
Surgery Partners Earnings release: Q1 2026
Surgery Partners released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Surgery Partners Slides: Q1 2026
Surgery Partners has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Surgery Partners Quarterly report: Q1 2026
Surgery Partners has published its Q1 2026 quarterly earnings report on May 5, 2026.
Surgery Partners reports Q1 adjusted EPS (3c), consensus (14c)
Reports Q1 revenue $810.9M, consensus $797.93M. Eric Evans, Chief Executive Officer, stated, “We are encouraged by our solid start to 2026, with same store revenue growth of 4.4% in line…
Surgery Partners backs FY26 revenue view $3.35B-$3.45B, consensus $3.41B
Backs FY26 adjusted EBITDA view at least $530M. The company said, “The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion…
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance
BRENTWOOD, Tenn., May 05, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announce...
Surgery Partners Proxy statement: Proxy filing
Surgery Partners filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Surgery Partners Proxy statement: Proxy filing
Surgery Partners filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Surgery Partners price target lowered to $15 from $16.25 at Jefferies
Jefferies lowered the firm’s price target on Surgery Partners (SGRY) to $15 from $16.25 and keeps a Buy rating on the shares. The relative underperformance of healthcare services stocks highlights…
Surgery Partners, Inc. Announces First Quarter 2026 Earnings Release Date and Conference Call Details
BRENTWOOD, Tenn., April 17, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced th...
Surgery Partners, Inc. Names Lloyd Dean to Board of Directors
BRENTWOOD, Tenn., March 12, 2026 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) recently announced that Lloyd Dean has been appointed to serve as an ind...
Surgery Partners Transcript: Barclays 28th Annual Global Healthcare Conference
Shifts in payer mix, particularly increased Medicare cases, compressed margins despite higher procedure volumes. Cost reduction, portfolio optimization, and a conservative approach to guidance are underway, with a focus on deleveraging and maintaining high patient experience.